Table 1.
Summary of characteristics of studies in the current meta-analysis. STRAW, Stages of Reproductive Aging Workshop; MDD, major depressive disorder; N/A, information not available; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition); RCT, randomized controlled trial; BDI, beck depression inventory; HAM-D, Hamilton Depression Rating Scale; GS, Greene Scale; QIDS-SR, quick inventory of depressive symptomatology; MADRS, Montgomery–Åsberg depression rating scale; CGI-S, clinical global impression-severity; CGI-I, clinical global impression-improvement.
| Author (year)Ref | Menstrual status | Other diagnosis | Criteria | Design | Comparison | N | Duration (weeks) | Outcome | Mean age (years) | Country |
|---|---|---|---|---|---|---|---|---|---|---|
|
Davari- Tanha (2016)29 |
Postmenopausal (STRAW staging system) | N/A | N/A | RCT | Venlafaxine75 mg/d | 20 | 8 | BDI (−) | 51.0 | Iran |
| Citalopram 20 mg/d | 20 | |||||||||
| Placebo | 20 | |||||||||
|
Macias-Cortes (2015)12 |
Peri-menopausal: Change in cycle length of seven days or longer in either direction from the participant’s own baseline for at least two cycles, or Late transition to menopause (i.e., three to 11 months of amenorrhea) OR Post-menopausal (i.e., 12 months or more of amenorrhea) |
MDD | DSM-IV | RCT | Fluoxetine 20 mg/d | 39 | 6 |
BDI (−) HAM-D (+) GS (−) Response rate (HAM-D) Remission rate (HAM-D) |
49.2 | Mexico |
| Placebo | 37 | 48.8 | ||||||||
|
Clayton (2013)11 |
Peri- menopausal: The presence of any of the following within 6 months before baseline: 1. Absolute change ≥7 days in menstrual cycle length, or 2. Change in menstrual flow amount (2 or more flow categories), or 3. Change in duration of menses (≥2 days), or 4. Amenorrhea lasting ≥3 months OR Post-menopausal: 1. Amenorrhea >12 months 2. Amenorrhea between 6–12 month with FSH > 40 mIU/mL, or 3. Amenorrhea >6 months post bilateral oophorectomy |
MDD | DSM-IV | RCT | Desvenlafaxine 50 mg/d | 185 | 10 |
HAM-D (+) QIDS-SR MADRS (+) CGI-S Response rate (HAM-D) Remission rate (HAM-D) Response rate (CGI-I) |
53.2 | USA |
| Placebo | 178 | 52.8 | ||||||||
|
Cheng (2013)16 |
Menopausal: 1. Amenorrhea >12 months 2. Amenorrhea between 6–12 month with FSH > 40 mIU/mL, or 3. Amenorrhea >6 months post bilateral oophorectomy) |
N/A | N/A | RCT | Desvenlafaxine100 mg/day | 153 | 12 |
POMS-TMD GS – depression (+) |
53.4 | USA |
| Desvenlafaxine 150 mg/day | 152 | |||||||||
| Placebo | 153 | |||||||||
|
Kornstein (2010)30 |
Peri-menopausal: The presence of any of the following within 6 months of baseline: 1. Absolute change of 7 days or more in menstrual cycle length, or 2. Change in menstrual flow amount (2 or more flow categories, e.g., from light or moderately light to moderately heavy or heavy), or 3. Change in duration of menses (absolute change of 2 or more days); and periods of amenorrhea lasting at least 3 months. OR Post-menopausal: 1. Amenorrhea >12 months, or 2. Amenorrhea >6 months post bilateral oophorectomy) |
MDD | DSM-IV | RCT | Desvenlafaxine100–200 mg/d | 212 | 8 |
HAM-D (+) QIDS-RS MADRS (+) CGI-S CGI-I Response rate (HAM-D) Remission rate (HAM-D) Response rate (CGI-I) |
52.0 | USA |
| Placebo | 109 | 53.0 | ||||||||
|
Soares (2008)31 |
Peri- or menopausal (STRAW staging system) | N/A | N/A | RCT | Paroxetine 25 mg/day | 50 | 6 | MADRS (+) | 55.6 | Canada |
| Placebo | 50 | 57.0 | ||||||||
|
Suvanto-Luukkonen (2005)17 |
Postmenopausal: Amenorrhea >6 months with FSH > 30 IU/L) |
N/A | N/A | RCT | Fluoxetine 20 mg/d | 50 | 36 | BDI (-) | 54.0 | Finland |
| Citalopram 30 mg/day | 49 | 54.0 | ||||||||
| Placebo | 50 | 54.0 |